Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 5/20 | 0.38 |
| ▸ | HTR4 | Q13639 | 5/20 | 0.38 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1024203 | 1.00 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2HTR3AHTR4PRMT5 | |
| SCHEMBL1024202 | 1.00 | CYP2D6 (0.44) | CYP2D6SMN1; SMN2HTR3AHTR4PRMT5 | |
| SCHEMBL8391173 | 0.80 | MEN1 (0.52) | SMN1; SMN2KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL9819626 | 0.80 | MEN1 (0.52) | SMN1; SMN2KDM4EMEN1KMT2AHSD17B10 | |
| SCHEMBL2619230 | 0.75 | CYP2D6 (0.70) | CYP2D6SMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL9478639 | 0.75 | KDM4E (0.51) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL9502114 | 0.73 | PKM (0.57) | CYP2D6SMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL488808 | 0.72 | MEN1 (0.68) | CYP2D6SMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL2485840 | 0.72 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2KDM4EALDH1A1MEN1 | |
| SCHEMBL357967 | 0.72 | CYP2D6 (0.51) | CYP2D6SMN1; SMN2KDM4EALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003664-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-7786136-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | disclosed |
| EP-1807423-B1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7498442-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2009-03-03 | — | — | US | disclosed |
| US-7419989-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2008-09-02 | — | — | US | disclosed |
| US-20080167295-A1 | Containing a nortropane ring, e.g., 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[2-hydroxy-3-(4-methanesulfonylpiperazin-1-yl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; 5-HT4 receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-07-10 | — | — | US | disclosed |
| US-7396933-B2 | Quinolinone-carboxamide compounds | THERAVANCE, INC. (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080132491-A1 | Indazole-carboxamide compounds | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-06-05 | — | — | US | disclosed |
| CN-101080406-A | Indazole-carboxamide compounds | THERAVANCE INC (US) | 2007-11-28 | — | — | CN | disclosed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | HTR4, HTR5A, HTR3B | CYP2D6 594/4885SMN1; SMN2 3386/4885HTR3A 7/4885 |
| US-20080132491-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | CYP2D6 594/4885SMN1; SMN2 3386/4885HTR3A 7/4885 |
| US-20060135764-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | CYP2D6 594/4885SMN1; SMN2 3386/4885HTR3A 7/4885 |
| US-20080167295-A1 | Containing a nortropane ring, e.g., 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[2-hydroxy-3-(4-methanesulfonylpiperazin-1-yl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; 5-HT4 receptor agonists | HTR5A, HTR4, HTR1A | CYP2D6 626/4885SMN1; SMN2 2609/4885HTR3A 6/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | CYP2D6 685/4885SMN1; SMN2 3575/4885HTR3A 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.